CYP3A5 gene polymorphism and risk of prostate cancer in a Japanese population

Li Zhenhua; Norihiko Tsuchiya; Shintaro Narita; Takamitsu Inoue; Yohei Horikawa; Hideaki Kakinuma; Tetsuro Kato; Osamu Ogawa; Tomonori Habuchi

doi:10.1016/j.canlet.2005.03.009

CYP3A5 gene polymorphism and risk of prostate cancer in a Japanese population

Cancer Lett. 2005 Jul 28;225(2):237-43. doi: 10.1016/j.canlet.2005.03.009.

Authors

Li Zhenhua¹, Norihiko Tsuchiya, Shintaro Narita, Takamitsu Inoue, Yohei Horikawa, Hideaki Kakinuma, Tetsuro Kato, Osamu Ogawa, Tomonori Habuchi

Affiliation

¹ Department of Urology, Akita University School of Medicine, 1-1-1 Hondo, Akita 010-8543, Japan.

PMID: 15876487
DOI: 10.1016/j.canlet.2005.03.009

Abstract

The CYP3A5 gene (CYP3A5) encodes the cytochrome P450 3A5, which catalyzes the 6beta-hydroxylation of testosterone. We explored association between the CYP3A5 A6986G polymorphism and a risk of prostate cancer in 260 prostate cancer patients, 199 BPH patients and 212 male controls. The CYP3A5 gene polymorphism did not influence significantly a risk of developing of prostate cancer in general. However, compared with males with the GG genotype, those with the AA genotype had a 0.23-fold decreased risk of developing low-grade prostate cancer (P=0.023), and a 0.31-fold decreased risk of developing localized (stages A-C) prostate cancer (P=0.044). The CYP3A5 A6986G polymorphism may be specifically associated with a decreased risk of low-grade or early stage prostate cancer.

Publication types

Research Support, Non-U.S. Gov't

MeSH terms

Aged
Cytochrome P-450 CYP3A
Cytochrome P-450 Enzyme System / genetics*
Genetic Predisposition to Disease / genetics*
Genotype
Humans
Japan
Male
Polymorphism, Genetic / genetics*
Prostatic Neoplasms / genetics*

Substances

Cytochrome P-450 Enzyme System
CYP3A protein, human
CYP3A5 protein, human
Cytochrome P-450 CYP3A